Log in to save to my catalogue

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8eb58697caf4466e8a01b8253f2d212f

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

About this item

Full title

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Publisher

London: Nature Publishing Group UK

Journal title

Scientific reports, 2021-11, Vol.11 (1), p.21396-14, Article 21396

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression of cancers such as hepatocellular carcinoma (HCC). This study investigated the relationship between the...

Alternative Titles

Full title

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8eb58697caf4466e8a01b8253f2d212f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8eb58697caf4466e8a01b8253f2d212f

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-021-00889-0

How to access this item